Serum-based DNA methylation biomarkers in colorectal cancer: Potential for screening and early detection

Thomas Summers, Russell C. Langan, Aviram Nissan, Björn L.D.M. Brücher, Anton J. Bilchik, Mladjan Protic, Martin Daumer, Itzhak Avital, Alexander Stojadinovic

Research output: Contribution to journalArticlepeer-review


Colorectal cancer (CRC) is the third most common cause of cancer-related death in the United States. Early identification and treatment of pre-cancerous colorectal lesions, or node-negative CRC are highly effective interventions that substantially reduce disease-specific mortality. Colonoscopy remains a highly effective primary screening tool based on its excellent diagnostic accuracy, and its ability to remove pre-cancerous lesions. However, the nature of the procedure limits compliance with colonoscopy intended for population-based CRC screening. A significant advance in the screening and care of these patients could be realized by blood-based biomarkers, which could accurately identify patients at-risk for CRC development whom might benefit from early and/or more frequent surveillance for disease. We reviewed and herein discuss the potential for serum based DNA methylation biomarkers for screening and early detection of CRC.

Original languageEnglish
Pages (from-to)210-216
Number of pages7
JournalJournal of Cancer
Issue number3
StatePublished - 2013
Externally publishedYes


  • Biomarker
  • Colorectal cancer
  • DNA methylation
  • Early detection
  • Screening
  • Serum


Dive into the research topics of 'Serum-based DNA methylation biomarkers in colorectal cancer: Potential for screening and early detection'. Together they form a unique fingerprint.

Cite this